Trump administration urged to take on China's 'Pharma Death Grip'

The Trump administration is being urged to tackle imported generic pharmaceuticals, most of which are made in China, due to national security implications.

Sen. Rick Scott (R-FL), chairman of the Senate Special Committee on Aging, wants the Commerce Department to consider using Section 232 national security tariffs on imported generic medicines and their ingredients. Such a move would frame the U.S. pharmaceutical supply chain as a national security vulnerability rather than a purely economic issue.